Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06362889 Not yet recruiting - Clinical trials for Acne Vulgaris (Disorder)

Evaluating Microneedling With CBD and Hempseed Oil for Acne Vulgaris Safety and Efficacy

Start date: May 2024
Phase: Phase 1
Study type: Interventional

This is a prospective, single center, open label study to assess the safety and effectiveness of microneedling with CBD and hempseed oil for the treatment of moderate to severe acne in adults 22-years of age or older.The objective of this exploratory study is to evaluate the safety and efficacy of HealMD's CBD with hempseed oil to reduce the appearance of moderate to severe facial acne.

NCT ID: NCT06340984 Not yet recruiting - Acne Vulgaris Clinical Trials

Serum Intercellular Adhesion Molecule -1 in Acne Vulgaris Patients : Effect of Montelukast

Start date: June 2024
Phase: Phase 3
Study type: Interventional

The aim of this study is to: 1. Evaluation of serum soluble intercellular adhesion molecule-1 (sICAM-1) level in acne vulgaris and compare it to control group 2. Evaluate its role in acne pathogenesis and its correlation with acne vulgaris severity 3. Evaluate the effect of Montelukast on serum (sICAM-1) level in acne vulgaris

NCT ID: NCT06248008 Not yet recruiting - Acne Clinical Trials

A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris

Start date: April 24, 2024
Phase: Phase 3
Study type: Interventional

This is a multicenter, open-label study designed to determine the long-term safety of ASC40 (Denifanstat) tablets in patients with moderate to severe acne vulgaris enrolled in the ASC40-303 Phase III study. All subjects are eligible for study eligibility screening after enrollment in ASC40-303 Phase III study, and all eligible subjects with moderate to severe acne vulgaris will receive ASC40 (Denifanstat) tablets after signing informed consent. The investigational drug will be administered orally once daily (QD) for up to 40 weeks. There will be a total of 7 visits for screening and follow-up. The tests required by the program included routine blood tests, blood biochemistry, lipid profile, pregnancy test and urine routine, etc.

NCT ID: NCT06237387 Not yet recruiting - Acne Vulgaris Clinical Trials

Association of Acne Vulgaris With Oral Hygiene and Gingivitis

Start date: February 10, 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about in the relationship between acne vulgaris and oral hygiene and gingivitis. The main questions it aims to answer are: - Is there a relationship between the severity of acne vulgaris lesions and the severity of plaque-related gingivitis? - Could oral hygiene or the severity of plaque-related gingivitis have an impact on the treatment of acne lesions? Participants will; - First be examined at the dermatology clinic. - Then be examined at the periodontology clinic. - Participants with severe acne vulgaris lesions will be examined a second time at the dermatology clinic. (1.5 months after the first examination) - Regularly use the antibiotic containing 100 mg doxycycline prescribed in the dermatology clinic for acne treatment. (Patients deemed suitable by the dermatologist)

NCT ID: NCT06225570 Not yet recruiting - Acne Vulgaris Clinical Trials

Weekly Isotretinoin vs Tetracycline for Moderate Acne

Start date: February 2024
Phase: Early Phase 1
Study type: Interventional

In the effort to find better treatments for Moderate Acne, which often relies on long-term antibiotic use, researchers are exploring alternative options. While Isotretinoin, a Vitamin A derivative, is highly effective for severe acne, its side effects limit its use for milder cases. A recent study from our institution investigated a new approach: weekly Isotretinoin dosing. The results were promising, with acne improvement and no major side effects. This suggests that weekly Isotretinoin could be a successful alternative for moderate acne in both males and females. To validate these findings, investigators propose a randomized controlled trial comparing weekly Isotretinoin to daily Doxycycline over four months. This study could confirm the safety and effectiveness of weekly Isotretinoin, as well as shed light on patient satisfaction, and long-term results compared to standard antibiotics. This research may offer a breakthrough in treating moderate acne while addressing concerns about antibiotic overuse.

NCT ID: NCT06175819 Not yet recruiting - Acne Vulgaris Clinical Trials

Efficacy of Manuka Honey Nano-Formulation in the Treatment of Acne Vulgaris

Start date: January 2024
Phase: N/A
Study type: Interventional

The present study aims to manufacture manuka honey-loaded nano-formulation using natural materials as a potent tissue-healing remedy and compare it to commercially available antimicrobial therapy in order to reduce the severity and recurrences of skin lesions.

NCT ID: NCT06158061 Not yet recruiting - Acne Vulgaris Clinical Trials

Assessment of Serum and Tissue Tryptase Levels in Acne Vulgaris Patients

Start date: January 24, 2024
Phase: N/A
Study type: Interventional

Acne vulgaris is an inflammatory disorder of pilosebaceous glands. Acne is a highly prevalent inflammatory disease affecting approximately 9.4% of the world's population , and estimated up to 90% among adolescents. By natural course acne starts at 7-12 ages and mostly resolves by the third decade of individuals life . Mast cells may play important role in maintenance of physiological functions of our body; they also have a role in pathological and inflammatory mechanisms of many diseases. Tryptase is suggested to be important for survival as no tryptase-deficient human subject has yet been reported. Tryptase is mainly synthesized by mast cells but a very low amount may originate in basophil with no interference with total levels of the enzyme. Tryptase is currently considered as a metabolic signaling and effector mediator for acute mast cell degranulation and late phase of allergy and inflammation .

NCT ID: NCT06142487 Not yet recruiting - Acne Vulgaris Clinical Trials

Assessment of the Effects of Silk Pillowcases on Acne Prone Skin

Start date: November 10, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effects of using silk pillowcases in mild to moderate non-cystic acne prone skin in comparison to cotton pillowcases.

NCT ID: NCT06141330 Not yet recruiting - Acne Vulgaris Clinical Trials

Vitamin D Supplementation in Acne

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare in acne vulgaris patients. The main question it aims to answer is: • To assess the therapeutic benefit of vitamin D supplement in acne vulgaris treatment, following a 2-month treatment regimen that includes vitamin D supplementation compared to conventional (systemic azithromycin and topical retinoid) treatment alone. Participants will receive vitamin D supplements in addition to capsule Azithromycin and topical retinoid. Researchers will compare groups to determine efficacy of Vitamin D supplements in the treatment of Acne vulgaris.

NCT ID: NCT05899699 Not yet recruiting - Acne Vulgaris Clinical Trials

Effect of New Topical Preparation for Treatment of Acne Vulgaris

Start date: June 5, 2023
Phase: Phase 2
Study type: Interventional

The investigators propose a randomized, double-blind control trial study to evaluate the efficacy and safety of the optimized topical combination ME of the investigated drugs in the treatment of acne vulgaris containing DAP-FLU in comparison with standard therapy of Adapalene at Mansoura University Dermatology and Andrology Outpatient Clinic.